A new painless microneedle patch shows promise in reversing hair loss. The discussion focuses on potential new treatments beyond common options like Minoxidil, finasteride, and RU58841.
Latanoprost is discussed as a potential hair loss treatment, noted for its synergy with minoxidil and 5-AR inhibitors, but concerns include its effectiveness on scalp hair, cost, and potential skin darkening. Some users express interest in trying latanoprost or bimatoprost despite limited real-world evidence.
Microneedling before applying topical finasteride or dutasteride may enhance their effectiveness by increasing local absorption in the scalp, despite concerns about systemic absorption. Users discuss combining this method with oral treatments and minoxidil, noting potential benefits and side effects.
New hair loss treatments include topical and gel formulations combining finasteride and dutasteride, with added caffeine and melatonin. The user reports good results with the topical dutasteride.
The conversation is about hair loss treatment progress using dutasteride 0.5mg and oral minoxidil 3mg. Suggestions include adding topical minoxidil with tretinoin and considering micro needling or micro stamping for further improvement.
Finasteride, dutasteride, saw palmetto, caffeine, spironolactone, acetyltetrapeptides, tea tree oil, hydrocortisone, zinc pyrithione, latanoprost, melatonin, marine protein supplements, PRP, microneedling, and valproate are discussed as treatments for hair loss. DHT reduction and inflammation control are key strategies.
A user trying various treatments for hair loss, such as minoxidil, stemoyxidine, alfatradiol, and microneedling, with plans to add tretinoine and finasteride.
The conversation is about finding an alternative hair growth stimulator for someone who cannot use Minoxidil due to heart issues. The person is currently using topical dutasteride, azelaic acid, and occasional microneedling, and is considering options like retinyl palmitate, latanoprost, certizine, or tadalafil.
The conversation discusses the use of pyrrolidinyl diaminopyrmidine oxide (triaminodil) compared to minoxidil for hair loss treatment. The user is considering switching from 5% minoxidil to a product containing 5% triaminodil.
Microneedling combined with latanoprost may convert vellus hairs to transitional or terminal hairs. The user suggests using oral minoxidil to increase vellus hair, then applying a high concentration of latanoprost with microneedling for conversion.
The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.
Bimatoprost, latanoprost, and travoprost can aid hair regrowth but are costly and less effective than minoxidil. They work best when combined with minoxidil and finasteride.
A user discusses the potential of caffeine and DMG in shampoo for treating hair loss, citing a pending patent and personal plans to test it. They find it more convenient than using minoxidil, tretinoin, and microneedling.
The user noticed increased hair fullness after using a minoxidil and finasteride oral capsule but is unsure if the 1.25 mg minoxidil dose is sufficient. They are considering switching to a higher dose and are waiting for a dermatologist's advice.
Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.
The user has been using oral dutasteride 0.5mg, oral minoxidil 2mg, and topical minoxidil 5% for hair regrowth, along with microneedling. They have seen significant hair coverage improvement and are considering additional supplements for better results.
Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hair follicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.
New hair loss treatments include topical and gel formulations combining finasteride and dutasteride, with added caffeine and melatonin. The user reports positive results from using topical dutasteride.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.
The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.
The user is addressing hair loss with scalp botox, scalp massage, nizoral shampoo, various vitamins and supplements, and natural nitric oxide boosters like citrulline malate and beetroot powder. They are also considering a mouthpiece to reduce snoring and improve sleep.
After 8 months of using topical finasteride, hair miniaturization continues, raising concerns about its effectiveness. Microneedling is suggested as a possible complementary treatment.
Hair loss treatments Finasteride, Dutasteride, Pyrilutamide, and RU58841 have different mechanisms of action. They can be used individually or stacked for better protection against hair loss.
Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.
Reducing the dose of RU58841 from 25mg to 7.5mg topically helped minimize heart palpitations. Users discussed the cardiac effects of RU58841 and minoxidil, noting that no treatment is completely free of side effects.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
A 43-year-old male has been using oral minoxidil, finasteride, and dutasteride for hair loss, with some stabilization and thin hair growth but no significant cosmetic improvement. He is considering increasing microneedling frequency and exploring other options, as he is concerned about the lack of terminal hair growth.